This one-pill fixed-dose of a combination of Ledipasvir and Sofosbuvir is the most effective options for treating genotypes 1, 4, 5 and 6 Hep-C infection – as approved by the FDA. Hepatitis C virus BS5B polymerase is responsible for mediating HCV RNA replication and Sofosbuvir is a simple analog inhibitor of the same which, when combined with Ledipasvir, gives a revolutionary treatment drug with minimal side effects.